Omada’s rapid rally spotlights a key Eli Lilly partnership as growth investors hunt for newer health-tech plays
The Eli Lilly partner Omada has jumped more than 118% over roughly three months, according to a new market roundup, as the company appears to be working through a fresh market “base.”